{"protocolSection": {"identificationModule": {"nctId": "NCT00631488", "orgStudyIdInfo": {"id": "0893-015"}, "secondaryIdInfos": [{"id": "2007_646"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)", "officialTitle": "A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK0893 in Combination With Sitagliptin or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2016-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-21", "studyFirstSubmitQcDate": "2008-02-27", "studyFirstPostDateStruct": {"date": "2008-03-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-10-07", "resultsFirstSubmitQcDate": "2012-01-14", "resultsFirstPostDateStruct": {"date": "2012-02-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-30", "lastUpdatePostDateStruct": {"date": "2017-01-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 146, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-0893 + Sitagliptin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0893", "Drug: Sitagliptin", "Drug: Placebo for Metformin"]}, {"label": "MK-0893 + Metformin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: MK-0893", "Drug: Metformin", "Drug: Placebo for Sitagliptin"]}, {"label": "Sitagliptin + Metformin", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin", "Drug: Placebo for MK-0893"]}], "interventions": [{"type": "DRUG", "name": "MK-0893", "description": "Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).", "armGroupLabels": ["MK-0893 + Metformin", "MK-0893 + Sitagliptin"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).", "armGroupLabels": ["MK-0893 + Sitagliptin", "Sitagliptin + Metformin"], "otherNames": ["JANUVIA\u2122", "MK0431"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).", "armGroupLabels": ["MK-0893 + Metformin", "Sitagliptin + Metformin"], "otherNames": ["GLUCOPHAGE\u00ae"]}, {"type": "DRUG", "name": "Placebo for MK-0893", "description": "Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.", "armGroupLabels": ["Sitagliptin + Metformin"]}, {"type": "DRUG", "name": "Placebo for Sitagliptin", "description": "Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).", "armGroupLabels": ["MK-0893 + Metformin"]}, {"type": "DRUG", "name": "Placebo for Metformin", "description": "Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).", "armGroupLabels": ["MK-0893 + Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)"}], "secondaryOutcomes": [{"measure": "Change From BL to Week 4 in Fasting Plasma Glucose (FPG)", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)"}, {"measure": "Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)"}, {"measure": "Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC", "description": "Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)"}, {"measure": "Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC", "description": "GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy\n\nExclusion Criteria:\n\n* Participants have a history of Type 1 Diabetes Mellitus\n* Participants taking insulin or thiazolidinediones (TZDs: peroxisome proliferator-activated receptor \\[PPAR\\]-gamma agonists)\n* Participants who have a contraindication to metformin or sitagliptin", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants received matching placebos to MK-0893, Sitagliptin, and Metformin during a 2-week run-in period.", "groups": [{"id": "FG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "FG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "FG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "49"}, {"groupId": "FG002", "numSubjects": "49"}]}, {"type": "Completed Post-Treatment Period", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "47"}, {"groupId": "FG002", "numSubjects": "47"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "47"}, {"groupId": "FG002", "numSubjects": "47"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "BG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "BG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "49"}, {"groupId": "BG003", "value": "146"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.6", "spread": "8.0"}, {"groupId": "BG001", "value": "52.0", "spread": "9.7"}, {"groupId": "BG002", "value": "53.8", "spread": "8.7"}, {"groupId": "BG003", "value": "53.2", "spread": "8.8"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "57"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "89"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels", "populationDescription": "Full Analysis Set Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)", "groups": [{"id": "OG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "OG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "OG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-85.7", "spread": "4.6", "lowerLimit": "4.6", "upperLimit": "-117.4"}, {"groupId": "OG001", "value": "-117.4", "spread": "4.6", "lowerLimit": "-99.6", "upperLimit": "4.6"}, {"groupId": "OG002", "value": "-99.6", "spread": "4.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+sitagliptin provide greater reduction in 24-hour WMG than sitagliptin+metformin. Using a standard deviation (SD) of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 24-hour WMG between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval (CI) for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "13.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.2", "ciUpperLimit": "22.7"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+metformin provide greater reduction in 24-hour WMG than sitagliptin+metformin. Using a standard deviation (SD) of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 24-hour WMG between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.5", "ciUpperLimit": "-9.2"}]}, {"type": "SECONDARY", "title": "Change From BL to Week 4 in Fasting Plasma Glucose (FPG)", "populationDescription": "Full Analysis Set Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)", "groups": [{"id": "OG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "OG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "OG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-73.7", "spread": "4.4"}, {"groupId": "OG001", "value": "-101.9", "spread": "4.3"}, {"groupId": "OG002", "value": "-82.8", "spread": "4.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+sitagliptin provide greater reduction in 24-hour FPG than sitagliptin+metformin. Using a standard deviation (SD) of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 24-hour FPG between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.050", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "9.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0", "ciUpperLimit": "18.2"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+metformin provide greater reduction in 24-hour FPG than sitagliptin+metformin. Using a standard deviation (SD) of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 24-hour FPG between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.0", "ciUpperLimit": "-10.1"}]}, {"type": "SECONDARY", "title": "Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC)", "populationDescription": "Full Analysis Set Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg.h/dL", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)", "groups": [{"id": "OG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "OG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "OG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-187.7", "spread": "11.4"}, {"groupId": "OG001", "value": "-254.9", "spread": "11.1"}, {"groupId": "OG002", "value": "-210.3", "spread": "11.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+sitagliptin provide greater reduction in 2-hr Glucose AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Glucose Total AUC between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.056", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "22.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.6", "ciUpperLimit": "45.8"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+metformin provide greater reduction in 2-hr Glucose AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants per group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Glucose Total AUC between any 2 treatment groups for a two-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% confidence interval for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-44.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-67.3", "ciUpperLimit": "-21.8"}]}, {"type": "SECONDARY", "title": "Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC", "description": "Glucagon-Like Peptide-1 (GLP-1) is an incretin hormone that acts as a potent insulin secretegogue in response to nutrient ingestion and stimulates glucose disposition. The total AUC of Total GLP-1 levels was calculated from blood sample data measured after the morning meal.", "populationDescription": "Full Analysis Set Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol*h/L", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)", "groups": [{"id": "OG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "OG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "OG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.4", "spread": "1.0"}, {"groupId": "OG001", "value": "16.4", "spread": "1.0"}, {"groupId": "OG002", "value": "3.2", "spread": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+sitagliptin provide greater reduction in 2-Hour Total GLP-1 Total AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants/group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Total GLP-1 Total AUC between any 2 treatment groups for a 2-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% CI for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "4.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.7", "ciUpperLimit": "6.7"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+metformin provide greater reduction in 2-Hour Total GLP-1 Total AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants/group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Total GLP-1 Total AUC between any 2 treatment groups for a 2-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% CI for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "13.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.7", "ciUpperLimit": "15.7"}]}, {"type": "SECONDARY", "title": "Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC", "description": "GLP-1 is cleaved from proglucagon to form the active peptide GLP-1. The active form promotes suppression of glucagon secretion. The total AUC of Active GLP-1 levels was calculated from blood sample data measured after the morning meal.", "populationDescription": "Full Analysis Set Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmole*h/L", "timeFrame": "BL, 4 weeks (end of double-blind treatment period)", "groups": [{"id": "OG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period."}, {"id": "OG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}, {"id": "OG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.0", "spread": "1.1"}, {"groupId": "OG001", "value": "6.3", "spread": "1.1"}, {"groupId": "OG002", "value": "17.6", "spread": "1.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+sitagliptin provide greater reduction in 2-Hour Active GLP-1 Total AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants/group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Active GLP-1 Total AUC between any 2 treatment groups for a 2-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% CI for the between group difference", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.5", "ciUpperLimit": "-3.8"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Hypothesis: After 4 weeks of treatment, MK-0893+metformin provide greater reduction in 2-Hour Active GLP-1 Total AUC than sitagliptin+metformin. Using a SD of 23.5 mg/dL, a sample size of 40 participants/group had 80% power to detect a true difference of 15 mg/dL in the mean change from BL in 2-Hour Active GLP-1 Total AUC between any 2 treatment groups for a 2-sided test at alpha=0.05, with a half-width of 10.3 mg/dL around the 95% CI for the between group difference.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Longitudinal Data Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.1", "ciUpperLimit": "-8.5"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5.0", "eventGroups": [{"id": "EG000", "title": "MK-0893 + Sitagliptin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period. Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period.", "seriousNumAffected": 0, "seriousNumAtRisk": 48, "otherNumAffected": 7, "otherNumAtRisk": 48}, {"id": "EG001", "title": "MK-0893 + Metformin", "description": "Participants received an initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 orally (40 mg tablets) administered daily throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period.", "seriousNumAffected": 0, "seriousNumAtRisk": 49, "otherNumAffected": 10, "otherNumAtRisk": 49}, {"id": "EG002", "title": "Sitagliptin + Metformin", "description": "Sitagliptin was administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period. Participants received Metformin orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin was then administered throughout the double-blind treatment period.", "seriousNumAffected": 0, "seriousNumAtRisk": 49, "otherNumAffected": 8, "otherNumAtRisk": 49}], "otherEvents": [{"term": "diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 49}, {"groupId": "EG002", "numEvents": 9, "numAffected": 6, "numAtRisk": 49}]}, {"term": "nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 48}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 49}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 49}]}, {"term": "upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 48}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 49}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 49}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Denmark", "France", "Germany", "Mexico", "Spain", "Sweden", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}